Loading
Life sciences · Journal article
Acs Omega · October 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Natural products represent an important source of candidates for breast cancer therapy. Here, we investigated the antitumor activity of (E)-4-(1-epoxy-7,8-propen)phenylbenzoate (CV2), a phenylpropanoid isolated from Croton velutinus roots, in MCF-7 breast cancer cells and evaluated its toxicity profile in nontumor cells and zebrafish embryos. CV2 exhibited potent cytotoxic activity against MCF-7 cells (IC50= 4.63 ± 0.16 μM) and showed selectivity relative to nontumorigenic MCF-10A cells (SI = 9.69). CV2 also induced apoptosis, increased intracellular ROS levels, and modulated MAPK, NF-κB, and PKB/AKT signaling pathways. Pretreatment with N-acetylcysteine or MAPK inhibitors significantly attenuated CV2-induced cytotoxicity, supporting the involvement of oxidative stress and MAPK signaling in its biological effects. In toxicity studies, CV2 exhibited cytotoxicity toward peripheral blood mononuclear cells (PBMCs; IC50 = 1.75 ± 0.06 μM) and an LC50 of 3.07 μM in zebrafish embryos, accompanied by alterations in oxidative stress-related enzymes. Collectively, these findings demonstrate that CV2 possesses significant antitumor activity against breast cancer cells while highlighting the need for further studies to better define its safety profile and therapeutic potential.